Ozempic, a GLP-1 receptor agonist prescribed for type 2 diabetes in the UK, works by enhancing insulin secretion, suppressing appetite, and slowing digestion
Typical Protocol: Commonly cited protocols use 1.5-1.6 mg subcutaneously two to three times per week (mirroring the Zadaxin regimen used in hepatitis trials), often run in 4 to 16 week cycles for general wellness use, with the original clinical trials using 1.6 mg twice weekly for 6 to 12 months
Long-term success depends on how your body is supported during and after treatment
Fatigue and energy changes Some researchers report transient fatigue when first combining the two compounds
In contrast, LCACs are thought to have the potential to activate inflammation, activating the NF-B luciferase reporter gene in RAW 264.7 cells in an acyl chain length- and concentration-dependent manner, as well as the phosphorylation of JNK and ERK [54, 55]